Summary
LLY Chart
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Research will leverage world's first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discovery of treatments that help individuals maintain and even improve their muscle mass and function REDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, today announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) to discover, develop, and commercialize drug candidates that improve muscle health and body composition.
Should You Buy Eli Lilly Stock Before June 22?
Eli Lilly (LLY 4.33%) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new data from studies relating to multiple GLP-1 drugs.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly and Company Dividends
 LLY 3 weeks ago | Other | €1.32 Per Share |
| LLY 3 months ago | Other | €1.32 Per Share |
| LLY 6 months ago | Other | €1.14 Per Share |
| LLY 9 months ago | Other | €1.14 Per Share |
| LLY 15 May 2024 | Other | €1.14 Per Share |
Eli Lilly and Company Earnings
| 7 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 2.7 Cons. EPS | 3.92 EPS |
| LLY 3 weeks ago | Other | €1.32 Per Share |
| LLY 3 months ago | Other | €1.32 Per Share |
| LLY 6 months ago | Other | €1.14 Per Share |
| LLY 9 months ago | Other | €1.14 Per Share |
| LLY 15 May 2024 | Other | €1.14 Per Share |
| 7 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | 2.7 Cons. EPS | 3.92 EPS |
Eli Lilly and Company (LLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Eli Lilly and Company ever had a stock split?
Eli Lilly and Company Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. David A. Ricks CEO | XSTU Exchange | US5324571083 ISIN |
| US Country | 47,000 Employees | 14 Feb 2025 Last Dividend | 16 Oct 1997 Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.
Products and Services
- Diabetes Care
Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.
- Oncology
Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.
- Immunology
Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Digestive Diseases
Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.
- Neurological Disorders
Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.
- Other Therapeutic Areas
The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.
Contact Information
